Sina Sharifi, PhD
Harvard Catalyst Profile Mass Eye and Ear Profile
Search
Search results
1026 results found
Menglu Yang, MD, PhD
Harvard Catalyst Profile Mass Eye and Ear Profile
Elizabeth Noyes, MD
Dr. Elizabeth “Liz” Noyes grew up in Harvard, Massachusetts, and graduated summa cum laude from the University of Massachusetts, Amherst, with a degree in neuroscience and anthropology. Following her undergraduate studies, she served as a researcher at the Center for Global Health Delivery-Dubai at...
Isabel Deakins, OD
Profiles Mass Eye and Ear Harvard Catalyst
Levi N. Kanu, MD
Profiles Mass Eye and Ear (clinical) Mass Eye and Ear (research) Harvard Catalyst Profile
Jacob Bernstein, B.A.
Jacob graduated from Connecticut College with a Bachelor of Arts in Neuroscience and minors in Statistics and Sociology. As an undergraduate he assisted with Professor Jeff Moher's cognitive research on attention and distraction. His studies there were focused on identifying physiological markers of...
Payel Ganguly
Payel completed her PhD from University of British Columbia, Vancouver where she used Drosophila as a model system to functionalize human gene variants involved in neurodevelopmental disorders. Currently she is a postdoctoral fellow in the Van Vactor and Artavanis lab where she is again using her...
Message from the Editor-in-Chief
Dear Colleagues, Research in gene augmentation and genome editing for the treatment of inherited retinal disorders (IRDs) is thriving. It is estimated that IRDs affect about 200,000- 300,000 people in the United States and 4-6 million people worldwide. Most patients with these conditions become...
Gene Therapy, Gene Editing, and IRDs
Gene-Augmentation Therapy Gene therapy typically refers to gene-augmentation therapy. In this approach, a healthy version of the mutated gene is packaged inside an engineered and nonpathogenic form of adeno-associated virus (AAV), with the virus serving as a vector to carry the gene. AAV does not...
Gene Therapy for Other Ophthalmic Conditions
Advances in the future may include viral vectors, non-viral vectors, and delivery methods that allow treatment of a greater retinal expanse and an expanded approach to technical challenges related to gene size and disease mechanisms. Genetic therapies for non-retinal ophthalmic diseases are also...